ArticleFrontiers in oncology2025
Recurrence of hepatocellular carcinoma in patients with high HALP score in TACE combined with ablation.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Machine Learning-Based Nomogram for Predicting Overall Survival in BCLC Stage 0-B Hepatocellular Carcinoma Patients with Low HALP Score.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate the relationship between the HALP score and recurrence in hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE) and ablation. Methods: We collected clinical data from 728 HCC patients who underwent TACE and ablation from January 2018 to December 2023. Patients with high HALP scores (H-HALP, n=422) were stratified into a training cohort (n=296) and an internal validation cohort (n=126), while an external validation cohort (n=147) was independently enrolled. Lasso-Cox regression was employed to identify independent risk factors for recurrence-free survival (RFS), and a nomogram was constructed. The predictive accuracy of nomogram was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Results: Although the median RFS in the H-HALP group longer than the L-HALP group (1.84 vs. 1.60 years, Conclusion: The HALP score alone showed limited prognostic value in this cohort; however, the Lasso-Cox regression-based nomogram effectively stratified recurrence risk in H-HALP patients treated with TACE and ablation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.